1. Show article details.

    What 5 Analyst Ratings Have To Say About Allogene Therapeutics

    Benzinga – 4:08 PM ET 08/10/2022

      Over the past 3 months, 5 analysts have published their opinion on Allogene Therapeutics stock. According to 5 analyst offering 12-month price targets in the last 3 months, Allogene Therapeutics has an average price target of $23.8 with a high of $35.00 and a low of $9.00. Below is a summary of how these 5 analysts rated Allogene Therapeutics over the past 3 months.

  2. Show article details.

    Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2022

    Benzinga – 10:11 AM ET 08/10/2022

      See all analyst ratings upgrades.   See all analyst ratings downgrades.   See all analyst ratings initiations.

  3. Show article details.

    BRIEF-Allogene Therapeutics Says U.S. FDA Clearance On Potential Pivotal Phase 2 Trial Of Allo-501A Anticipated In Coming Weeks

    Reuters – 5:08 PM ET 08/09/2022

    Allogene Therapeutics Inc (ALLO): * ALLOGENE THERAPEUTICS REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS. * U.S. FDA CLEARANCE ON POTENTIAL PIVOTAL PHASE 2 TRIAL OF ALLO-501A ANTICIPATED IN COMING WEEKS. * CASH BURN FOR 2022 IS NOW EXPECTED TO BE APPROXIMATELY $250 MILLION. * EXPENSES TO BE AT THE LOW END OF THE PREVIOUS RANGE OF $360 MILLION AND $390 MILLION FOR 2022.

  4. Show article details.

    Allogene Therapeutics: Q2 Earnings Insights

    Benzinga – 4:55 PM ET 08/09/2022

      Allogene Therapeutics reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Allogene Therapeutics beat estimated earnings by 14.75%, reporting an EPS of $-0.52 versus an estimate of $-0.61. Revenue was up $42 thousand from the same period last year.

  5. Show article details.

    Allogene Therapeutics Reports Second Quarter 2022 Financial Results

    GlobeNewswire – 4:02 PM ET 08/09/2022

    SOUTH SAN FRANCISCO, Calif., Aug. 09, 2022 -- Allogene Therapeutics (ALLO), Inc. , a clinical-stage biotechnology company pioneering the development of allogeneic CAR T products for cancer, today provided a corporate update and reported financial results for the quarter ended June 30, 2022.

  6. Show article details.

    Earnings Scheduled For August 9, 2022

    Benzinga – 5:02 AM ET 08/09/2022

      ** Cognition Therapeutics is estimated to report earnings for its second quarter. ** Gilat Satellite Networks is estimated to report quarterly loss at $0.01 per share on revenue of $56.24 million. ** Drive Shack is likely to report quarterly loss at $0.10 per share on revenue of $82.58 million. ** ReWalk Robotics is projected to report earnings for its second quarter.

  7. Show article details.

    Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences

    GlobeNewswire – 8:30 AM ET 08/03/2022

    Allogene Therapeutics, Inc. (ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T products for cancer, today announced that management plans to participate in three upcoming investor conferences. 42nd Annual Canaccord Genuity Growth ConferenceThursday, August 11, 2022Noon PT/3:00PM ET.

  8. Show article details.

    Allogene Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022

    GlobeNewswire – 8:30 AM ET 07/27/2022

    Allogene Therapeutics, Inc. (ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T products for cancer, today announced that it will report second quarter 2022 financial results on Tuesday, August 9, 2022, after the close of the market.

  9. Show article details.

    Beyond Meat, Canoo, Veru And More: 12 Short Squeeze Candidates To Watch

    Benzinga – 10:28 AM ET 07/20/2022

    One of the most powerful tradable market events is a short squeeze, so traders are always on the lookout for the next short squeeze candidate. The Squeeze Score incorporates S3's Crowded Score, a measure of a stock's total short interest, short percent of float, stock loan liquidity and trading liquidity.

  10. Show article details.

    Benzinga's Top Ratings Upgrades, Downgrades For July 15, 2022

    Benzinga – 10:18 AM ET 07/15/2022

      See all analyst ratings upgrades.   See all analyst ratings downgrades.   See all analyst ratings initiations.

  11. Show article details.

    12 Health Care Stocks Moving In Friday's Pre-Market Session

    Benzinga – 8:14 AM ET 07/15/2022

      This article was generated by Benzinga's automated content engine and reviewed by an editor.

  12. Show article details.

    Allogene Therapeutics Appoints Scientific Pioneer Stephen Mayo to its Board of Directors

    GlobeNewswire – 8:30 AM ET 07/12/2022

    Allogene Therapeutics, Inc. (ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T products for cancer, today announced the appointment of Stephen L. Mayo, Ph.D., a world renowned expert in computational protein design, to the company’s Board of Directors.

  13. Show article details.

    89 Biggest Movers From Friday

    Benzinga – 4:44 AM ET 06/21/2022

  14. Show article details.

    BRIEF-Allogene Therapeutics Announces The FDA Granted Regenerative Medicine Advanced Therapy Designation To Allo-501A For Large B Cell Lymphoma

    Reuters – 8:41 AM ET 06/08/2022

    Allogene Therapeutics Inc (ALLO): * ALLOGENE THERAPEUTICS ANNOUNCES THE FDA GRANTED REGENERATIVE MEDICINE ADVANCED THERAPY DESIGNATION TO ALLO-501A FOR LARGE B CELL LYMPHOMA. * Allogene Therapeutics Inc (ALLO) - INTENDS TO INITIATE A PHASE 2 PIVOTAL TRIAL IN MID-2022 Source text for Eikon: Further company coverage:

  15. Show article details.

    Allogene Therapeutics Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to ALLO-501A for Large B Cell Lymphoma

    GlobeNewswire – 8:30 AM ET 06/08/2022

    SOUTH SAN FRANCISCO, Calif., June 08, 2022 -- Allogene Therapeutics, Inc. (ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T products for cancer, today announced that the U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy designation to ALLO-501A in relapsed/refractory LBCL.

  16. Show article details.

    Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2022

    Benzinga – 10:08 AM ET 06/03/2022

      See all analyst ratings upgrades.   See all analyst ratings downgrades.   See all analyst ratings initiations.

  17. Show article details.

    What 4 Analyst Ratings Have To Say About Allogene Therapeutics

    Benzinga – 9:09 AM ET 06/03/2022

    Analysts have provided the following ratings for Allogene Therapeutics within the last quarter: These 4 analysts have an average price target of $11.25 versus the current price of Allogene Therapeutics at $7.87, implying upside. Below is a summary of how these 4 analysts rated Allogene Therapeutics over the past 3 months.

  18. Show article details.

    Allogene Therapeutics Announces Oral Presentation of Pre-Clinical Data Highlighting Improved Anti-Tumor Activity of Donor-Derived Allogeneic CAR T Cells at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

    GlobeNewswire – 8:30 AM ET 05/19/2022

    SOUTH SAN FRANCISCO, Calif., May 19, 2022 -- Allogene Therapeutics, Inc. (ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T products for cancer, today will present preclinical findings evaluating the characteristics and function of donor-derived allogeneic CAR T cells.

  19. Show article details.

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

    Benzinga – 8:09 AM ET 05/17/2022

      This article was generated by Benzinga's automated content engine and reviewed by an editor.

  20. Show article details.

    Why This Analyst Has 'Little Conviction' On CRISPR's Upcoming Trial Data

    Benzinga – 2:23 PM ET 05/10/2022

    Why This Analyst Has 'Little Conviction' On CRISPR's Upcoming Trial Data

Page:

Today's and Upcoming Events

  • Nov
    02

    ALLO to announce Q3 earnings (Unconfirmed)

Past Events (last 90 days)

  • Aug
    09

    ALLO announced Q2 earnings.

Data provided by Thomson Reuters © 2022

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.